Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin) [3]

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 5, 2002, Pages 813-814

  Melamed, Julian ^a   Stahlman, Jon E ^b  

^a Allergy and Asthma Specialists   (United States)

^b Family Allergy and Asthma Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; GLYCERYL TRINITRATE; NAVELBINE; PACLITAXEL; PETHIDINE; RANITIDINE; TRASTUZUMAB;

ADULT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL PROTOCOL; DESENSITIZATION; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HYPERTENSION; IMMUNOTHERAPY; LETTER; PRIORITY JOURNAL;

EID: 0036857422     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.128689     Document Type: Letter

References (3)

1. Eiermann W. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data. Ann Oncol 2001;12 Suppl 1:S57-62.
2. McKeage K, Perry CM. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002;62:209.
3. Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991;66:343-6.